FDA has approved Pertuzumab [Perjeta] in combination with Trastuzumab [Herceptin] and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer
![FDA has approved Pertuzumab [Perjeta] in combination with Trastuzumab [Herceptin] and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer](https://thasso.com/wp-content/uploads/2012/06/Breast-Cancer-II-African-II.png)
June 11, 2012 – The American Food and Drug Administration (FDA) has approved Pertuzumab [Perjeta]. Pertuzumab [Perjeta] is approved in combination with Trastuzumab [Herceptin] and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have …